表紙
市場調查報告書

胱天蛋白酶9:開發中產品分析

Caspase 9 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 365752
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
胱天蛋白酶9:開發中產品分析 Caspase 9 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 70 Pages
簡介

本報告提供以胱天蛋白酶9為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胱天蛋白酶9 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Bellicum Pharmaceuticals, Inc.
  • Conatus Pharmaceuticals Inc.
  • LG Life Science LTD.
  • Novelix Pharmaceuticals, Inc.
  • Pharmedartis GmbH

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1990TDB

Summary

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Caspase 9 - Pipeline Review, H2 2019, outlays comprehensive information on the Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Caspase-9 is an initiator caspase encoded by the CASP9 gene. Binding of caspase-9 to Apaf-1 leads to activation of the protease which cleaves and activates caspase-3. It is involved in the activation cascade of caspases responsible for apoptosis execution. It promotes DNA damage-induced apoptosis in an ABL1/c-Abl-dependent manner. The molecules developed by companies in Phase III and Preclinical stages are 2 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology and Toxicology which include indications Age Related Macular Degeneration, Bladder Cancer, Chemotherapy Induced Neutropenia, Colorectal Cancer, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Prostate Cancer, Small-Cell Lung Cancer and Solid Tumor.

Furthermore, this report also reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)
  • The report reviews Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Overview
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Companies Involved in Therapeutics Development
  • Bellicum Pharmaceuticals Inc
  • BeyondSpring Inc
  • Clayton Biotechnologies Inc
  • Marine Biomedical Research Institute of Qingdao
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Drug Profiles
  • flavokawain A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Activate Caspases for Age Related Macular Degeneration, Diabetic Retinopathy and Solid Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MBRI-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • plinabulin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rimiducid + rivogenlecleucel - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate Caspase 8, 9 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Dormant Products
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Discontinued Products
  • Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2019: BeyondSpring's study 106 phase 3 superior trial design combining plinabulin with pegfilgrastim versus pegfilgrastim alone for chemotherapy-induced neutropenia presented at ASH 2019 Annual Meeting
  • Dec 09, 2019: BeyondSpring's abstracts on clinical evidence for bone marrow stem cell protection as plinabulin's mechanism of action for CIN accepted at American Society of Hematology's 2019 Annual Meeting
  • Nov 11, 2019: BeyondSpring's single-blinded design of phase 3 study 103 (DUBLIN-3) prevented premature patient drop-out: Data Accepted for Presentation at SITC 2019
  • Oct 23, 2019: BeyondSpring enrolls first patient in global phase 3 clinical trial with Plinabulin in combination with G-CSFto prevent chemotherapy-induced neutropenia
  • Oct 17, 2019: BeyondSpring's Lead Asset, Plinabulin, granted U.S. patent covering methods of treating brain tumors
  • Oct 08, 2019: Cell journals publishes BeyondSpring's announces prenew data on mechanism of plinabulin to mature dendritic cells, leading to t-cell activation
  • Oct 01, 2019: BeyondSpring presents novel trial design for DUBLIN-3 study BPI-2358-103 at ESMO Congress 2019
  • Sep 23, 2019: BeyondSpring's Plinabulin continues to build on superior product profile in breast cancer trial for neutropenia prevention
  • Sep 10, 2019: BeyondSpring's Novel Study 103 Phase 3 Design in NSCLC Presented at 2019 IASLC World Conference on Lung Cancer
  • Aug 23, 2019: BeyondSpring plinabulin demonstrates superior quality of life over pegfilgrastim in a head-to-head comparison trial for the prevention of neutropenia
  • May 20, 2019: BeyondSpring abstract demonstrating bone pain benefit with lead asset, Plinabulin, versus Neulasta for neutropenia prevention Presented at ISPOR 2019
  • May 16, 2019: BeyondSpring's rationale for the plinabulin-neulasta combination for neutropenia prevention accepted as abstracts at 2019 ASCO Annual Meeting
  • Mar 26, 2019: BeyondSpring's lead asset, Plinabulin, shifts the balance of macrophages towards anti-cancer M1s
  • Mar 25, 2019: BeyondSpring advancing patient targeting strategies for lead asset Plinabulin
  • Mar 20, 2019: BeyondSpring to present clinical trial data on lead asset, Plinabulin, at 2019 St. Gallen International Breast Cancer Conference
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
  • Pipeline by BeyondSpring Inc, H2 2019
  • Pipeline by Clayton Biotechnologies Inc, H2 2019
  • Pipeline by Marine Biomedical Research Institute of Qingdao, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top